Evidence map›Paper›PMID 37345154›Full record

ArticleCancers2023

Netrin Family Genes as Prognostic Markers and Therapeutic Targets for Clear Cell Renal Cell Carcinoma: Netrin-4 Acts through the Wnt/β-Catenin Signaling Pathway.

Shuai Ke, Jiayu Guo, Qinghua Wang, Haoren Shao, Mu He, Tao Li, Tao Qiu, Jia Guo

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shuai KeDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0001-9001-9028
Jiayu GuoDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Qinghua WangDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Haoren ShaoDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Mu HeDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Tao LiDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Tao QiuDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-1410-7795
Jia GuoDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Wuhan University · CN

Funding

National Natural Science Foundation of China 81702539
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC, or KIRC) is the most common type of kidney cancer, originating within the renal cortex. The current outcomes for early diagnosis and late treatment of ccRCC are unsatisfactory. Therefore, it is important to explore tumor biomarkers and therapeutic opportunities for ccRCC. In this study, we used bioinformatics methods to systematically evaluate the expression and prognostic value of Netrin family genes in ccRCC. Through our analysis, three potential biomarkers for ccRCC were identified, namely NTNG1, NTNG2, and NTN4. Moreover, we performed in vitro and in vivo experiments to explore the possible biological roles of NTN4 and found that NTN4 could regulate ccRCC development through Wnt/β-catenin signaling. We elucidate the molecular mechanism by which NTN4 modulates β-catenin expression and nuclear translocation to inhibit ccRCC progression, providing a new theoretical basis for developing therapeutic targets for ccRCC. Thus, we suggest that Netrin-related studies may offer new directions for the diagnosis, treatment, and prognosis of ccRCC patients.

Indexed as

clear cell renal cell carcinomanetrinprognosistherapeutic approachesWnt/β-catenin

Identifiers

PMID37345154
PMCPMC10216638
OpenAlexW4377108055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.